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McCune-Albright syndrome (MAS) is characterized by
fibrous dysplasia (FD), café-au-lait skin spots and precocious
puberty (PP). The syndrome may be associated with 
hyperfunction of other endocrine glands, such as  growth 
hormone excess, hyperprolactinoma, hyperthyroidism and
Cushing’s syndrome  (1,2,3). MAS is a rare disorder and its
prevalence is estimated to be between 1/100 000 and 1/1 000
000 (4). Activating somatic mutations of GNAS gene located
on chromosome 20q13 encoding the α-subunit of the 
regulatory Gsα protein are responsible for the entity (5,6). 
PP is the most common endocrinopathy seen  in  MAS
and occurs in 64-79% of girls and 15% of boys (3). Aromatase
inhibitors (testolactone, fadrazole, anastrozole, letrozole),
tamoxifen (selective estrogen reseptor modulator),
gonadotropin-releasing hormone (GnRH) analogues and 
surgery are the different treatment strategies employed in the
treatment of PP due to MAP (7). 
FD is reported in 46-98% of  MAS patients. FD presents
as an isolated lesion involving a single site in one third of
these patients.   Calcium and vitamin D supplementation,
intravenous pamidronate  therapy and surgical methods 
are used in the management of FD (8,9). The prevalence of
café-au-lait skin spots varies between 53.1% and 92.5% in
MAS (3).
In this report, we present  the long-term follow-up 
findings of a patient  diagnosed as  MAS. 
ABSTRACT
McCune-Albright syndrome (MAS) is characterized by the triad of
fibrous dysplasia (FD), cafe-au-lait spots and precocious puberty (PP).
We report a 14-year-old girl with MAS who has been followed-up for 8
years. She was referred for multiple fractures and vaginal bleeding at
age 5.9 years. She had peripheral PP, FD, and osteoporosis and was
diagnosed as MAS. The patient was treated with aromatase inhibitors
and bisphosphonates. She had no menses during aromatase inhibitor
treatment. Her growth rate and bone maturation were in normal ranges
while on treatment. She had one new fracture on the seventh year of
follow- up in spite of bisphosphonate treatment.  
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A 5.9-year-old girl was referred to our Pediatric
Endocrinology clinic for premature menarche and three 
fracture episodes that have occurred in the past year. On
physical examination, she was noted to have thelarche
(Tanner stage 2) and multiple café-au-lait skin spots.  Her
height was 116 cm (-0.35 SD). GnRH stimulation test
revealed suppressed gonadotropin levels (peak LH: 0.4
mIU/mL, peak FSH:0.92 mIU/mL) and an elevated estradiol
(E2) level  (29.8 pg/mL). Her bone age was 8 years, assessed
by the Greulich-Pyle method.  On pelvic ultrasound, uterine
size was 30.3x12.3x11.9 mm,  the dimensions of the right
ovary were 18.5 x15 mm and those of the left  ovary 16.8 x
15.3 mm. A follicle  cyst 11 mm in diameter was detected in
the right ovary without any other pathology. The serum level
of thyrotropin (TSH) was 0.09 mIU/mL (normal: 0.6-5.5
mIU/mL), of free thyroxine (T4) 1.41 ng/dL (normal: 0.8- 1.9
ng/dL) and that of free triiodothyronine (T3) was 4.57 pg/mL
(normal: 2-7.6 pg/mL). TSH levels were suppressed after
thyrotropin-releasing hormone (TRH) administration. Thyroid
autoantibodies were negative. Multinodular goiter  was 
present on thyroid ultrasound. Bone scintigraphy revealed
increased activity concordant with FD in the   craniofacial
bones, in the right femur and right humerus. She had a  
lumbar spine Z-score of -2.7 on dual-energy X-ray 
absorptiometry (DXA) scan. Serum cortisol, prolactin, growth
hormone, insulin-like growth factor-1 (IGF-1) and IGF-binding
protein-3 (IGFBP-3) levels were in normal  ranges. Based on
the coexistence of PP, FD and café-au-lait skin spots, the
patient was diagnosed as MAS. 
Testolactone (200 mg/day) therapy was initiated. After
the first year of treatment,    testolactone was discontinued.
Anastrazole was started and used for four years. On this
treatment, serum E2 levels ranged between 29 and 59.3
pg/mL, LH - 0.15 and 0.2 mIU/mL, and FSH between 0.1 and
2 mIU/mL.  Pelvic ultrasonography revealed uterine volume
between 6.2 and 10.2 ml with persisting follicular cysts of 
23-32 mm in diameter. Growth rate was 6 cm/year during
this period. Anastrozole treatment was discontinued when
the patient reached  11 years of age. At this time, she was at
pubertal stage 3, with a bone age of 12 years. She started to
have spontaneous menses six months after  discontinuation
of anastrazole therapy. Her menstruation periods were 
irregular at the beginning, but she has had regular menses in
the past three years. She was 153.8 cm (-0.9 SD), 50.1 kg 
(-0.1 SD) and had achieved Tanner stage B5 in her recent
control when she was 14 years old. 
As  we investigated  for other endocrinopathies, we
found that  she had subclinic hyperthyrodism; she was 
followed up  with beta- blocker therapy during the first four
years. Subclinic hyperthroidism status had  come to an end
on the fifth year and beta-blocker treatment was terminated.
Subclinical hyperthyroidism status resolved in the fifth year
and beta-blocker treatment was terminated. Her ultrasound
scans were concordant with multinodular goiter and the 
fine-needle aspiration biopsy specimens showed benign
cytology. Our patient was in euthyroid status without any
treatment during the last four years. Thyroid  ultrasound  and
fine-needle aspiration biopsy were planned to be annually
performed. During the follow-up period, no other
endocrinopathies (e.g. hypercortisolism, hyperprolactinoma
or growth hormone excess) that may accompany MAS were
noted. There  was no  pathology on the MR images of the
sella either.           
For FD and osteoporosis, three cycles of pamidronate
(1mg/kg/cycle every four months) were given  in the first
year. Then,  the  therapy was continued with oral etidronate
and vitamin D plus calcium supplementation. In the third year
after the diagnosis, she had a lumbar spine Z-score of -0.1 on
DXA scan and experienced no fractures during this period.
Treatment was therefore discontinued. However, because of
abnormal findings on plain X-ray films, intravenous
pamidronate (2 mg/kg/cycle every six months) and calcium,
as well as vitamin D treatment were restarted on the sixth
year of follow-up when she was 11 years old. Despite this
treatment, the patient had one new fracture in the seventh
year of follow-up when she was under pamidronate therapy
and her bone mineral density (BMD) L1-L4 Z-score was 0.29.
Serum calcium, phosphate, alkaline phosphatase and
parathormone levels were in normal ranges during follow-up
and there was no phosphate wasting or hyperparathyrodism.
Discussion
MAS  is defined as the  triad of  FD, café-au-lait skin spots
and  PP. Other pathologies such as hyperthyroidism, growth
hormone excess, renal phosphate wasting (with or without
rickets/osteomalacia), Cushing’s syndrome, as well as 
liver, parathyroid, pancreas and heart involvement may
accompany MAS (2). Activating mutations in exon 8 of GNAS
gene is the cause of this disorder. These  mutations lead to
impaired  GTPase   activity and  result in cAMP increase and
unregulated  hormone production. Mutation formation is a
post-zygotic somatic event. Hence, there is a mosaic 
distribution of cells containing the mutation and there is a
great variability in tissue involvement and disease severity
(1,6,10).
PP is the most common endocrinopathy seen in MAS. PP
affects girls more often than boys and frequently, vaginal
bleeding is the initial sign. Autonomic activation of ovarian 
tissue  leads to ovarian follicular cysts and estrogen 
hypersecretion. This status is defined as peripheral PP since
hypothalamic-pituitary-gonadal axis is inactive. However, 
progression to central PP may occur at follow-up (7,11).
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Follow-up of McCune-Albright SyndromeHistorically, ketoconazole and medroxyprogesterone were
used in the treatment of PP. Medroxyprogesterone does not
seem to have an effect on accelerated skeletal maturation,
but may stop  the vaginal bleeding. Treatment approaches
include anti-estrogens  (aromatase inhibitors-testolactone,
fadrozole, anastrozole, letrozole), estrogen receptor blockers 
(tamoxifen), GnRH analogues (if there is a progression to
central PP) and surgical methods (unilateral oophorectomy,
cystectomy) (7). Nunez et al (12) indicated that  fadrazole is
not effective and must not be used as it may cause adrenal
insufficiency. Feuillan et al (13) reported that testolactone can
be used in the treatment of PP since it leads to a decrease in
ovarian volume and estrogen levels. In another study, these
same authors found that letrazole is an effective agent in the
treatment of PP in MAS (14). 
Our patient did not have menses under aromatase
inhibitor treatment and peripheral PP did not progress to 
central  PP. There was no significant increase in ovarian 
volumes when she was receiving testolactone. However,
the follicle cysts in the right ovary persisted on serial 
sonographic examinations. Although anastrazole may be 
ineffective (15), it was found to be beneficial in our patient.
Although it has been reported that the pituitary-gonadal 
axis may frequently be suppressed in late adolescence or
adulthood  due to persisting ovarian hyperfunction and 
hyperestrogenism seen in these subjects (11), our patient
had regular menses and her gonadotropin levels were within
the pubertal reference ranges. Most of the reported MAS
cases have oligo-amenorrhea or hypermenorrhea and rarely,
regular menstrual periods. There may be infertility problems
secondary to ovarian hyperfunction and this underlines the
need for close follow-up of ovarian function in women with
MAS. 
It has been reported that thyroid involvement occurs in
approximately 30% of MAS patients (16). Hyperthyroidism in
MAS is associated with an  increase in the free T3/ free T4
ratio. Free T4 levels are  mildly elevated or normal.
Autoimmunity does not  accompany this status (16).
Multinodular goiter may be detected by ultrasonography. Our
case also received  beta-blocker  treatment for subclinical
hyperthyroidism during the first  four years after the 
diagnosis.
It has been shown that bisphosphonate treatment
decreases fracture rate and pain in FD (17). FD lesions have
high interleukin (IL)-6 levels leading to increased osteolytic
activity. Bisphosponate treatment prevents this by inhibiting
IL-6  (18). The levels of  osteoblastic/osteolytic markers
decrease secondary to bisphosphonate therapy (8).
Nevertheless, it has been reported that calcium and vitamin D
supplementation is the first step in FD treatment. Bone pain
is a  clear indication for bisphosphonate treatment in 
childhood (8,9). We prescribed bisphosphonates to our
patient as she complained from fractures, bone pain and had
a low BMD at diagnosis.   On therapy, she did not suffer from
bone pain and her BMD increased. We did not observe any
side effects secondary to this treatment. However, our
patient had a new fracture under bisphosphonate treatment
in spite of the increase in BMD. 
MAS is a rare disease and there is no consensus or 
sufficient experience regarding the time to terminate PP
treatment and about the problems that may occur during the
late adolescent or adult period. 
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